Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities

Podobne zapisy

• Bcr-Abl tyrosine kinase inhibitors- current status
  od: Mughal, Anum, i wsp.
  Wydane: (2013)
• The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
  od: Hantschel, Oliver, i wsp.
  Wydane: (2007)
• Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors
  od: Byrgazov, Konstantin, i wsp.
  Wydane: (2016)
• Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
  od: Carofiglio, Francesca, i wsp.
  Wydane: (2020)
• A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL
  od: Tong, Bingqi, i wsp.
  Wydane: (2020)